McKesson Corporation Announces Fourth Quarter Fiscal 2024 Earnings Release Date
IRVING, Texas, March 27, 2024 —McKesson Corporation (NYSE: MCK) will release its fourth quarter and full year fiscal 2024 financial results after market close on Tuesday, May 7, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review ... (Source: McKesson News)
Source: McKesson News - March 27, 2024 Category: Information Technology Source Type: news

McKesson Invites Community Pharmacists to Push the Industry Forward, Together
IRVING, TX, March 14, 2024 —Registration is now open for McKesson ideaShare in New Orleans from June 23–26, 2024. The annual event is the destination for community pharmacists to come together to strengthen the overall health of pharmacy and elevate the role they play in people’s lives. Attendees can... (Source: McKesson News)
Source: McKesson News - March 14, 2024 Category: Information Technology Source Type: news

McKesson ’s Practice Insights Designated as a 2024 Qualified Clinical Data Registry by Centers for Medicare & amp; Medicaid Services
IRVING, Texas, Feb. 8, 2024 — For the eighth consecutive year, McKesson has received approval from the Centers for Medicare& Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System (MIPS) as a Qualified Clinical Data Registry (QCDR). The designation enables healthcare pra... (Source: McKesson News)
Source: McKesson News - February 8, 2024 Category: Information Technology Source Type: news

McKesson Corporation Reports Fiscal 2024 Third Quarter Results and Raises Full Year Guidance
Third Quarter Highlights: (Source: McKesson News)
Source: McKesson News - February 7, 2024 Category: Information Technology Source Type: news

McKesson Corporation Declares Quarterly Dividend
IRVING, Texas, February 1, 2024 —The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 62 cents per share of common stock. The dividend will be payable on April 1, 2024, to stockholders of record on March 1, 2024. (Source: McKesson News)
Source: McKesson News - February 1, 2024 Category: Information Technology Source Type: news

McKesson to Present at the 42nd Annual J.P. Morgan Healthcare Conference
IRVING, Texas, January 9, 2024 —McKesson Corporation (NYSE: MCK) will present at the 42nd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco today at 9:45 AM PT (12:45 PM ET). Executive leadership will provide a company overview followed by a fireside chat. (Source: McKesson News)
Source: McKesson News - January 9, 2024 Category: Information Technology Source Type: news

McKesson Corporation Announces Third Quarter Fiscal 2024 Earnings Release Date and Participation in January Conference
IRVING, Texas, December 27, 2023 — McKesson Corporation (NYSE: MCK) will release its third quarter fiscal 2024 financial results after market close on Wednesday, February 7, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its... (Source: McKesson News)
Source: McKesson News - December 27, 2023 Category: Information Technology Source Type: news

FABHALTA (iptacopan), FDA Approved for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria, Available at Biologics by McKesson
CARY, N.C., Dec. 20, 2023 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by Novartis as a specialty pharmacy provider for FABHALTA® (iptacopan). FABHALTA, approved by the U.S. Food and Drug Administration (FDA) on Dec. 5, 2023, is ... (Source: McKesson News)
Source: McKesson News - December 20, 2023 Category: Information Technology Source Type: news

The US Oncology Network Further Expands Its Nashville, Tennessee Footprint and Research Expertise with the Addition of SCRI Oncology Partners
THE WOODLANDS, Texas, Dec. 19, 2023 — The US Oncology Network (The Network), the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, announced today that SCRI Oncology Partners has joined The Network. SCRI Oncology Partners, located in Nashville, Te... (Source: McKesson News)
Source: McKesson News - December 19, 2023 Category: Information Technology Source Type: news

Crystal Lennartz Named President of Health Mart & amp; Health Mart Atlas
IRVING, TX, Dec. 13, 2023 —McKesson appoints Crystal Lennartz, Pharm.D., MBA, to President of Health Mart®, an independent pharmacy franchise, and Health Mart Atlas™, a pharmacy services administrative organization (PSAO). (Source: McKesson News)
Source: McKesson News - December 13, 2023 Category: Information Technology Source Type: news

OGSIVEO (nirogacestat) FDA Approved for Desmoid Tumors, Available at Biologics by McKesson
CARY, N.C., Dec. 5, 2023 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected by SpringWorks Therapeutics as a limited distribution specialty pharmacy for OGSIVEOTM (nirogacestat), which is a gamma secretase inhibitor indicated for adult pa... (Source: McKesson News)
Source: McKesson News - December 5, 2023 Category: Information Technology Source Type: news

TRUQAP (capivasertib), FDA Approved for the Treatment of Breast Cancer, Available at Biologics by McKesson
CARY, N.C., Dec. 1, 2023 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by AstraZeneca as a specialty pharmacy provider for TRUQAPTM (capivasertib). TRUQAP, which was approved by the U.S. Food and Drug Administration (FDA) on Nov. 17... (Source: McKesson News)
Source: McKesson News - December 1, 2023 Category: Information Technology Source Type: news

FRUZAQLA (fruquintinib), FDA Approved for the Treatment of Metastatic Colorectal Cancer, Available at Biologics by McKesson
CARY, N.C., Nov. 15, 2023 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by Takeda as a specialty pharmacy provider for FRUZAQLATM (fruquintinib). FRUZAQLA, approved by the U.S. Food and Drug Administration (FDA) on Nov. 8, 2023, is ... (Source: McKesson News)
Source: McKesson News - November 15, 2023 Category: Information Technology Source Type: news

The US Oncology Network Extends Its Reach into Tennessee with The Addition of Nashville Oncology Associates
THE WOODLANDS, Texas, Nov. 13, 2023 — The US Oncology Network (The Network), the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, announced today that Nashville Oncology Associates (NOA) has joined The Network, effective October 1st. (Source: McKesson News)
Source: McKesson News - November 13, 2023 Category: Information Technology Source Type: news

McKesson Corporation Reports Fiscal 2024 Second Quarter Results and Raises Full Year Guidance
Second  Quarter Highlights: (Source: McKesson News)
Source: McKesson News - November 1, 2023 Category: Information Technology Source Type: news